In this article, we are going to address the topic of Denileukin diftitox from a broad and detailed perspective. Denileukin diftitox is a topic of great relevance in today's society, since it impacts various aspects of daily life. Along these lines, we are going to explore the different facets of Denileukin diftitox, analyzing its causes, consequences and possible solutions. Furthermore, we will examine the role that different actors play in relation to Denileukin diftitox, as well as the ethical and moral implications it entails. Ultimately, this article aims to offer a comprehensive view of Denileukin diftitox, with the aim of providing the reader with a deeper and enriching understanding of this very relevant topic.
Clinical data | |
---|---|
Trade names | Ontak |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611024 |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 70-80 min |
Identifiers | |
| |
CAS Number | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C2560H4042N678O799S17 |
Molar mass | 57647.46 g·mol−1 |
(what is this?) (verify) |
Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these.
In 1999, Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).
There is some evidence tying it to vision loss, and in 2006 the FDA added a black box warning to the drug's label.
In 2014, marketing of Ontak was discontinued in the US.